【レポートの概要（一部）】
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Assumptions
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Overview: Immunotherapy
• Types of immunotherapy
• Key events
• Reimbursement policies
• Orphan drug designation and regulatory approvals
PART 06: Pipeline portfolio
• Anticipated number of immuno-oncology pipeline assets with single and multiple indications by 2020
PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 08: Market segmentation by type of immunotherapy
• mAbs
• Immune checkpoint inhibitors
• Vaccines
• Non-specific immunotherapies
PART 09: Market segmentation by therapy area
PART 10: Geographical segmentation
• Global immunotherapy drugs market by geographical segmentation 2015-2020
• Immunotherapy drugs market in Americas
• Immunotherapy drugs market in EMEA
• Immunotherapy drugs market in APAC
PART 11: Market drivers
• Growing prevalence of cancer and autoimmune diseases
• Rise in older population
• Increase in demand for mAbs
• Patient assistance programs
• Promising pipeline
PART 12: Impact of drivers
PART 13: Market challenges
• Patent expiries of top-selling drugs
• High costs of biologicals
• Poor diagnosis and screening
• Adverse effects
• Stringent regulations
PART 14: Impact of drivers and challenges
PART 15: Market trends
• Increase in awareness programs
• Emergence of targeted and combination therapies
• Emergence of biosimilars
• Strategic alliances
• Expected entry of novel vaccines
PART 16: Vendor landscape
• Competitive scenario
• Market share analysis 2015
• F. Hoffmann-La Roche
• AbbVie
• Johnson & Johnson
• Merck
• Amgen
• BMS
• Other prominent vendors
PART 17: Appendix
• List of abbreviations
PART 18: Explore Technavio
[List of Exhibits]
Exhibit 01: Product offerings
Exhibit 02: Types of immunotherapy
Exhibit 03: Key events in discovery and approvals of immunotherapy drugs
Exhibit 04: Immunotherapy drugs approved by US FDA in 2015
Exhibit 05: US FDA orphan drug designations and approvals list for immunotherapy drugs
Exhibit 06: EU orphan drug designations and approvals list for immunotherapy drugs
Exhibit 07: Phase III pipeline molecules for mAbs
Exhibit 08: Phase II pipeline molecules for mAbs
Exhibit 09: Phase I pipeline molecules for mAbs
Exhibit 10: Pipeline molecules for immune checkpoint inhibitors
Exhibit 11: Phase III pipeline molecules for vaccines
Exhibit 12: Phase II pipeline molecules for vaccines
Exhibit 13: Phase I pipeline molecules for vaccines
Exhibit 14: Near-launch immuno-oncology pipeline assets
Exhibit 15: Global immunotherapy drugs market 2015-2020 ($ billions)
Exhibit 16: Factors influencing global immunotherapy drugs market
Exhibit 17: Challenges faced by US immunologists while prescribing immunotherapy drugs 2015
Exhibit 18: SWOT analysis of global immunotherapy drugs market
Exhibit 19: Five forces analysis
Exhibit 20: Market segmentation by type of immunotherapy drug
Exhibit 21: Timeline of mAbs approval for cancer by US FDA
Exhibit 22: Timeline of mAbs approval for autoimmune, respiratory, and ophthalmic diseases by US FDA
Exhibit 23: Global mAbs market 2015-2020 ($ billions)
Exhibit 24: Key drivers and challenges of global monoclonal antibodies drugs market
Exhibit 25: Top vendor offerings in global mAbs market
Exhibit 26: Global immune checkpoint inhibitors market 2015-2020 ($ billions)
Exhibit 27: Key driver and challenge for global immune checkpoint inhibitors market
Exhibit 28: Top vendor offerings in global immune checkpoint inhibitors market
Exhibit 29: Global vaccines market 2015-2020 ($ billions)
Exhibit 30: Segmentation of global vaccines market by application 2015
Exhibit 31: Key drivers and challenges of global vaccines market
Exhibit 32: Top vendor offerings in global vaccines market
Exhibit 33: Global non-specific immunotherapies market 2015-2020 ($ billions)
Exhibit 34: Key drivers and challenges of global non-specific immunotherapies market
Exhibit 35: Top vendor offerings in global non-specific immunotherapies market
Exhibit 36: Segmentation of global immunotherapy drugs market by type of immunotherapy 2015
Exhibit 37: Global immunotherapy drugs market; YoY revenue and growth rate based on type of immunotherapy 2015-2020 ($ billions)
Exhibit 38: Global immunotherapy drugs market segmentation by therapy area
Exhibit 39: Segmentation of global immunotherapy drugs market by therapy area 2015
Exhibit 40: Segmentation of global immunotherapy drugs market by geography 2015
Exhibit 41: Global immunotherapy drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 42: Immunotherapy drugs market in Americas 2015-2020 ($ billions)
Exhibit 43: Market share in the Americas by type of immunotherapy 2015
Exhibit 44: Immunotherapy drugs market in EMEA 2015-2020 ($ billions)
Exhibit 45: Market share in Europe by type of immunotherapy 2015
Exhibit 46: Immunotherapy drugs market in APAC 2015-2020 ($ billions)
Exhibit 47: Market share in APAC by type of immunotherapy 2015
Exhibit 48: Global immunotherapy drugs market: YoY revenue and growth based on geography 2015-2020 ($ billions)
Exhibit 49: Global incidence of cancers 2015 and 2020
Exhibit 50: Population aged 60 years and over: World, developed, and developing regions (millions)
Exhibit 51: Patient assistance programs for immunotherapy drugs
Exhibit 52: Some pipeline molecules for immunotherapy drugs
Exhibit 53: Impact of drivers
Exhibit 54: Approvals and patent expiries of top-selling immunotherapy drugs
Exhibit 55: Average annual treatment cost per patient for some immunotherapy drugs 2014 ($ millions)
Exhibit 56: Impact of drivers and challenges
Exhibit 57: Expected combination regimen launches in immune-oncology 2015-2020
Exhibit 58: Market share analysis of top vendors0
Exhibit 59: Competitive assessment of top 10 immunotherapy drugs 2015 ($ billions)1
Exhibit 60: YoY sales comparison of top five immunotherapy drugs 2013-2015 ($ billions)1
Exhibit 61: F. Hoffmann-La Roche: Immunotherapy drugs segmentation by revenue 20152
Exhibit 62: F. Hoffmann-La Roche: Top-selling immunotherapy drugs 20152
Exhibit 63: F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan (oncology and immunology indications) 2013-2015 ($ billions)
Exhibit 64: F. Hoffmann-La Roche: YoY revenue and growth rate of MabThera/Rituxan (immunology indications only) 2013-2015 ($ billions)4
Exhibit 65: F. Hoffmann-La Roche: YoY revenue and growth rate of Actemra/RoActemra 2013-2015 ($ billions)5
Exhibit 66: F. Hoffmann-La Roche: Actemra/RoActemra geographic segmentation by revenue 20155
Exhibit 67: F. Hoffmann-La Roche: MabThera/Rituxan geographic segmentation by revenue 20156
Exhibit 68: F. Hoffmann-La Roche: YoY revenue and growth rate of Avastin 2012-2015 ($ billions)7
Exhibit 69: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin 2012-2015 ($ billions)8
Exhibit 70: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in US 2013-2015 ($ billions)8
Exhibit 71: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in EU 2013-2015 ($ billions)8
Exhibit 72: F. Hoffmann-La Roche: YoY revenue and growth rate of Herceptin in Japan 2013-2015 ($ millions)9
Exhibit 73: F. Hoffmann-La Roche: YoY revenue and growth rate of Perjeta 2012-2015 ($ billions)0
Exhibit 74: F. Hoffmann-La Roche: YOY revenue and growth rate of Kadcyla 2013-2015 ($ billions)1
Exhibit 75: F. Hoffmann-La Roche: Key takeaways3
Exhibit 76: AbbVie: Immunotherapy drugs segmentation by revenue 20154
Exhibit 77: AbbVie: YoY revenue and growth rate of HUMIRA 2013-2015 ($ billions)5
Exhibit 78: AbbVie: YoY revenue and growth rate of HUMIRA in US 2013-2015 ($ billions)5
Exhibit 79: AbbVie: YoY revenue and growth rate of HUMIRA in ROW 2013-2015 ($ billions)5
Exhibit 80: AbbVie: Sales of HUMIRA in major markets 20156
Exhibit 81: AbbVie: Key takeaways7
Exhibit 82: Johnson & Johnson: Key immunotherapy drugs segmentation by revenue 20158
Exhibit 83: Johnson & Johnson: Top-selling immunotherapy drugs 20158
Exhibit 84: Johnson & Johnson: YoY revenue and growth rate of Remicade 2012-2015 ($ billions)9
Exhibit 85: Johnson & Johnson: YoY revenue and growth rate of Stelara 2012-2015 ($ billions)0
Exhibit 86: Johnson & Johnson: YoY revenue and growth rate of Stelara in US 2012-2015 ($ billions)0
Exhibit 87: Johnson & Johnson: YoY revenue and growth rate of Stelara in ROW 2012-2015 ($ millions)0
Exhibit 88: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria 2012-2015 ($ billions)1
Exhibit 89: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria in the US 2012-2015 ($ billions)1
Exhibit 90: Johnson & Johnson: YoY revenue and growth rate of Simponi/Simponi Aria in ROW 2012-2015 ($ billions)2
Exhibit 91: Johnson & Johnson: Key takeaways3
Exhibit 92: Merck: Business segmentation by revenue 20154
Exhibit 93: Merck: Immunotherapy drugs segmentation by revenue 20155
Exhibit 94: Merck: Top-selling immunotherapy drugs 20156
Exhibit 95: Merck: YoY revenue and growth rate of Gardasil/Gardasil9 2012-2015 ($ billions)7
Exhibit 96: Merck: YoY revenue and growth rate of ProQuad/M-M-R II/Varivax 2012-2015 ($ billions)8
Exhibit 97: Merck: YoY revenue and growth rate of Zostavax 2012-2015 ($ millions)8
Exhibit 98: Merck: YoY revenue and growth rate of Pneumovax 23 2012-2015 ($ millions)9
Exhibit 99: Merck: YoY revenue and growth rate of RotaTeq 2012-2015 ($ millions)9
Exhibit 100: Merck: Key takeaways2
Exhibit 101: Amgen: Top-selling immunotherapy drugs 20153
Exhibit 102: Amgen: YoY revenue and growth rate of Enbrel in US and Canada 2012-2015 ($ billions)4
Exhibit 103: Amgen: YoY revenue and growth rate of Enbrel in US 2012-2015 ($ billions)4
Exhibit 104: Amgen: YoY revenue and growth rate of Enbrel in Canada 2012-2015 ($ millions)4
Exhibit 105: Amgen: YoY revenue and growth rate generated from net product sales of Xgeva 2012-2015 ($ billions)5
Exhibit 106: Amgen: YoY revenue and growth rate generated from net product sales of Prolia 2012-2015 ($ billions)5
Exhibit 107: Amgen: YoY revenue and growth rate of Vectibix in US 2012-2015 ($ millions)6
Exhibit 108: Amgen: YoY revenue and growth rate of Vectibix in ROW 2012-2015 ($ millions)6
Exhibit 109: Amgen: Key takeaways9
Exhibit 110: BMS: Business segmentation by revenue 20150
Exhibit 111: BMS: Immunotherapy drugs segmentation by revenue 20150
Exhibit 112: BMS: Top-selling immunotherapy drugs 20151
Exhibit 113: BMS: YoY revenue and growth rate of Orencia 2012-2015 ($ billions)2
Exhibit 114: BMS: YoY revenue and growth rate generated from net product sales of Yervoy 2012-2015 ($ billions)2
Exhibit 115: BMS: YoY revenue and growth rate of Erbitux in US, Canada, and Japan 2012-2015 ($ millions)3
Exhibit 116: BMS: Key takeaways
【レポート販売概要】
■ タイトル：免疫治療薬の世界市場：モノクローナル抗体、免疫チェックポイント阻害薬、ワクチン、非特異的免疫療法■ 英文：Global Immunotherapy Drugs 2016-2020
■ 発行日：2016年3月29日
■ 調査会社：Technavio
■ 商品コード：IRTNTR8772
■ 調査対象地域：世界
- 手術用顕微鏡の世界市場Developing markets such as the Middle East, Brazil, Argentina, Mexico, China, and India are lucrative markets for surgical microscopes, owing to favorable government incentives. The report segments the surgical microscopes market is segmented on the basis of application, end user, and region. On the basis of applications, the surgical microscopes applications market is categorized into neuro & spi …
- ヘルスケア分野のビックデータ市場（Big Data in Healthcare）Medical data represents a large, rapidly growing, and mostly unstructured data residing in multiple locations including lab and imaging systems, physician notes, medical correspondence, claims, CRM and financial systems. With resizing costs with the healthcare industry, there is an imperative to reduce the cost of care and efficiently manage resources without compromising patient care. Healthcare …
- Acidity：グローバル臨床試験レビューH1, 2013Acidity Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, “Acidity Global Clinical Trials Review, H1, 2013" provides data on the Acidity clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acidity. It includes an overview of the trial numbers and their recruitment status as per the site of trial conductio …
- トップ15石油化学製品の世界市場予測（～2021）：エチレン、プロピレン、ベンゼン、ブタジエン、トルエン、キシレン、酸化エチレン、酸化プロピレン、メタノール、PE、PP、PVC、PS、PET、ABSThe top 15 petrochemicals report is divided into three sub parts, basic petrochemicals, basic intermediate chemicals and basic polymers. The basic petrochemicals market is projected to grow from 250.3 Million tons in 2016 to 310.3 Million tons by 2021, at a CAGR of 4.4% from 2016 to 2021. Rise in demand of commodity plastics in emerging economies in Southeast Asia and the Middle East. Moreover, ri …
- BreitBurn Energy Partners L.P.：石油・ガスの開発・生産動向及びコスト分析- Q2, 2013BreitBurn Energy Partners L.P. Oil & Gas Exploration and Production Operations and Cost Analysis - Q2, 2013 Summary BreitBurn Energy Partners L.P. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is a …
- Noble Energy, Inc.：石油・ガスバリューチェーン分析レポート2013Noble Energy, Inc. Analysis Across the Oil and Gas Value Chain Report, 2013 Update Summary "Noble Energy, Inc." Analysis Across the Oil and Gas Value Chain is an essential source for data, analysis and strategic insight into “Noble Energy, Inc.”. The report provides key information relating to oil and gas assets of the company along with its operations across the value chain. The report examines t …
- Hemophilia：グローバル臨床試験レビューH2, 2013Hemophilia Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Hemophilia Global Clinical Trials Review, H2, 2013" provides data on the Hemophilia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hemophilia. It includes an overview of the trial numbers and their recruitment status as per the site of tri …
- 炭素管理ソフトウェアの世界市場2015-2019About Carbon Management Software Carbon management software is a tool that aids organizations in planning and implementing their carbon management strategies. Carbon management tools help organizations accurately measure and reduce their carbon footprints, meet their objectives of corporate sustainability, and fulfill government mandates. The increasing amount of GHG emissions is a major concern f …
- スマート照明市場2014(Version1)：市場動因、予測NanoMarkets has been covering the smart lighting market for four years and has acquired an understanding of the key markets, technologies and companies in this rapidly expanding business. This year, NanoMarkets has decided to cover this interesting sector in two volumes. Volume I is devoted to an analysis of smart lighting markets and covering the basic drivers and economics of the smart lighting …
- VCSEL（ビクセル）の世界市場予測VCSELs are a type of lasers in which infrared energy is emitted from the surface cavity of semiconductor layers. Multiple devices can be packaged together to form an array and used for high-speed optical data communication over short distances. Their high reliability and low cost of fabrication have also encouraged manufacturers to develop these devices for sensing applications. In the last few ye …
- 中国のEV充電スタンド市場2016-2020About the Electric Vehicle Charging Station Market in China China has been aggressive in its efforts to promote EV adoption, primarily to cope with the growing pollution scenario. China was placed at the top of the nations with the most carbon dioxide emissions in 2011. China’s tremendous economic growth has been riding on the country’s manufacturing sector, which has been a key contributor to the …
- コンクリート補修モルタルの世界市場：PMCモルタル、エポキシモルタルThe global market size of concrete repair mortars is estimated to reach USD 2.62 Billion by 2021 at a CAGR of 7.67%. It is driven by the increased spending on repair and maintenance and rising trend of public-private partnership in developed economies. However, the global economic slowdown is hampering the consumption of repair concrete mortars. Different types of concrete repair mortars are also …
- 世界の積層セラミックコンデンサ市場2015The Global Multilayer Ceramic Capacitor Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Multilayer Ceramic Capacitor industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Multilayer Ceramic Capacitor market analysis is provided for the international m …
- アンモニアの世界市場動向及び予測2015The present report is an essential resource for a one looking for detailed information on the world ammonia market. The report covers data on global, regional and national markets including present and future trends for supply and demand, prices, and downstream industries. In addition to the analytical part, the report provides a range of tables and figures which all together give a true insight i …
- Pruritus：グローバル臨床試験レビューH2, 2013Pruritus Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Pruritus Global Clinical Trials Review, H2, 2013" provides data on the Pruritus clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pruritus. It includes an overview of the trial numbers and their recruitment status as per the site of trial condu …
